サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1795281

次世代の糖尿病治療とドラッグデリバリーの世界市場

Next Generation Diabetes Therapy and Drug Delivery

出版日
ページ情報
英文 177 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.92円
次世代の糖尿病治療とドラッグデリバリーの世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 177 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

次世代の糖尿病治療とドラッグデリバリーの世界市場は2030年までに341億米ドルに達する見込み

2024年に240億米ドルと推定される次世代の糖尿病治療とドラッグデリバリーの世界市場は、分析期間2024-2030年にCAGR 6.0%で成長し、2030年には341億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである吸入インスリンは、CAGR 4.9%を記録し、分析期間終了までに139億米ドルに達すると予測されます。経口インスリン・セグメントの成長率は、分析期間中CAGR 7.7％と推定されます。

米国市場は63億米ドルと推定、中国はCAGR6.0％で成長予測

米国の次世代の糖尿病治療とドラッグデリバリー市場は2024年に63億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに55億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.4%と5.2%と予測されています。欧州では、ドイツがCAGR 5.0%で成長すると予測されています。

世界の次世代の糖尿病治療とドラッグデリバリー市場- 主要動向と促進要因のまとめ

糖尿病治療の情勢はなぜ変わりつつあるのか？

次世代糖尿病治療薬は、より的を絞った効率的でユーザーフレンドリーなソリューションを提供することで、1型糖尿病と2型糖尿病の両方の患者の管理方法を変革しつつあります。従来の治療法では、1日に複数回のインスリン注射や経口血糖降下薬を使用することが多く、個別化には限界がありました。これとは対照的に、新たな治療法は、高精度のデリバリー、患者中心の設計、代謝転帰の改善に重点を置いています。技術革新は、低血糖リスク、治療アドヒアランス、グルコース変動といった根強い課題に取り組んでいます。

世界の糖尿病負担の増大は、心血管疾患、神経障害、腎障害といった長期的な合併症と相まって、先進的な治療に対する需要を強めています。早期介入モデル、血糖コントロールの重視、在宅医療へのシフトは、次世代システムの採用を促しています。患者は、利便性、リアルタイムモニタリング、最小限の侵襲性を兼ね備えた統合治療ソリューションを選択するようになってきています。

新しい薬剤クラス別とドラッグデリバリー・メカニズムは、治療経路をどのように再定義しているか？

いくつかの新しい薬剤クラスは、インスリンやメトホルミン以外の治療選択肢を広げています。GLP-1受容体作動薬、SGLT2阻害薬、デュアルアゴニストは、体重減少、心血管安全性、腎臓保護などの利点があるため、現在では2型糖尿病治療に不可欠な薬剤となっています。これらの薬剤は、週1回の注射剤、自動注射器、徐放性インプラントによって投与され、患者のコンプライアンスを改善し、副作用を最小限に抑えています。

投与メカニズムは急速に進化しており、インスリンポンプ、パッチポンプ、スマートペンが人気を集めています。クローズドループシステムは、しばしば人工膵臓と呼ばれ、持続的なグルコースモニタリングと自動化されたインスリン投与が組み合わされ、アルゴリズムに基づいたダイナミックな投与量調整が可能です。マイクロニードルアレイ、吸入可能なインスリン製剤、経口ペプチド製剤は、注射による障害をなくすために開発中です。これらの送達技術革新は、快適性と長期服薬アドヒアランスを促進しながら、治療精度を高めています。

糖尿病管理への技術導入を支える広範なヘルスケア動向とは？

デジタルヘルス統合は、次世代糖尿病治療の主要な実現要因です。接続されたインスリンペン、モバイルアプリ、クラウドベースのプラットフォームにより、データの共有、傾向の追跡、遠隔診察が可能になります。患者や臨床医は、投与量の最適化やライフスタイルの調整のためにリアルタイムのデータにアクセスできるようになり、個別化されたケアが強化されます。モニタリング機器とインスリン送達システム間の相互運用性により、特に小児や高齢者の使い勝手が向上しています。

ヘルスケアシステムは、アウトカム主導の介入を重視するバリューベースのケアモデルを徐々に採用しつつあります。このシフトは、入院の減少、生活の質の向上、合併症の予防といった長期的な利益をもたらす治療法や機器の使用を促しています。遠隔医療や在宅医療サービスの成長は、糖尿病治療の分散化をさらに後押ししています。先進治療に対する保険償還や国の糖尿病プログラムへの組み入れが、特に新興国市場での普及を加速させています。

次世代の糖尿病治療とドラッグデリバリー市場の成長を促進する要因とは？

次世代の糖尿病治療とドラッグデリバリー市場の成長は、いくつかの要因によってもたらされます。世界の糖尿病有病率の上昇により、革新的かつ効率的な治療モデルに対する持続的なニーズが高まっています。半減期が延長され、心代謝に有益な新規薬剤クラス別の導入により、薬理戦略が再構築されつつあります。クローズドループポンプやウェアラブル注射器を含むスマートデリバリーシステムの進歩は、コントロールと患者の自律性を向上させています。デジタル統合と遠隔治療の実現により、治療の個別化と臨床監視が強化されつつあります。保険償還範囲の拡大と統合ソリューションに対する規制当局の支援は、市場への迅速な参入と幅広いアクセスを促進しています。これらの動向は総体的に糖尿病管理を再定義し、先進的な治療薬と次世代デリバリー技術への需要を促進しています。

セグメント

製品タイプ（吸入インスリン、経口インスリン、インスリンパッチ、CGMシステム、人工膵臓）;適応症（1型糖尿病、2型糖尿病）;エンドユーザー（診断/クリニックエンドユーザー、集中治療室エンドユーザー、在宅ヘルスケアエンドユーザー）

調査対象企業の例

  • Abbott Laboratories
  • Beta Bionics, Inc.
  • Camurus AB
  • Dexcom, Inc.
  • Eli Lilly and Company
  • Enteris BioPharma
  • GlySens Incorporated
  • Johnson & Johnson
  • MannKind Corporation
  • Medtech S.A.
  • Medtronic plc
  • Nemaura Medical Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Relmada Therapeutics
  • Roche Holding AG
  • Sanofi S.A.
  • Senseonics Holding, Inc.
  • Tandem Diabetes Care, Inc.
  • Ypsomed AG
  • Zosano Pharma Corp.

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP37495

Global Next Generation Diabetes Therapy and Drug Delivery Market to Reach US$34.1 Billion by 2030

The global market for Next Generation Diabetes Therapy and Drug Delivery estimated at US$24.0 Billion in the year 2024, is expected to reach US$34.1 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Inhalable Insulin, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$13.9 Billion by the end of the analysis period. Growth in the Oral Insulin segment is estimated at 7.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.3 Billion While China is Forecast to Grow at 6.0% CAGR

The Next Generation Diabetes Therapy and Drug Delivery market in the U.S. is estimated at US$6.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$5.5 Billion by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.4% and 5.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Next Generation Diabetes Therapy and Drug Delivery Market - Key Trends & Drivers Summarized

Why Is the Landscape of Diabetes Therapy Undergoing a Transformation?

Next generation diabetes therapies are transforming how patients manage both Type 1 and Type 2 diabetes by offering more targeted, efficient, and user-friendly solutions. Traditional treatment approaches often involve multiple daily insulin injections or oral hypoglycemics with limited personalization. In contrast, the emerging therapeutic landscape focuses on precision delivery, patient-centric designs, and improved metabolic outcomes. Innovations are addressing persistent challenges such as hypoglycemia risk, therapy adherence, and glucose variability.

The growing global diabetes burden, coupled with long-term complications such as cardiovascular disease, neuropathy, and renal impairment, is intensifying demand for advanced therapies. Early intervention models, emphasis on glycemic control, and the shift toward home-based care are encouraging the adoption of next-generation systems. Patients are increasingly opting for integrated treatment solutions that combine convenience, real-time monitoring, and minimal invasiveness.

How Are Novel Drug Classes and Delivery Mechanisms Redefining Treatment Pathways?

Several new drug classes are expanding therapeutic options beyond insulin and metformin. GLP-1 receptor agonists, SGLT2 inhibitors, and dual agonists are now integral to Type 2 diabetes care due to their benefits in weight reduction, cardiovascular safety, and kidney protection. These agents are being delivered via weekly injectables, autoinjectors, and sustained-release implants that improve patient compliance and minimize side effects.

Delivery mechanisms are evolving rapidly, with insulin pumps, patch pumps, and smart pens gaining traction. Closed-loop systems, often termed artificial pancreas, combine continuous glucose monitoring with automated insulin delivery, allowing dynamic, algorithm-driven dosing adjustments. Microneedle arrays, inhalable insulin formulations, and oral peptide drugs are under development to eliminate injection-related barriers. These delivery innovations are enhancing therapeutic precision while promoting comfort and long-term adherence.

What Broader Healthcare Trends Are Supporting Technology Adoption in Diabetes Management?

Digital health integration is a major enabler of next-generation diabetes therapy. Connected insulin pens, mobile apps, and cloud-based platforms allow data sharing, trend tracking, and remote consultation. Patients and clinicians can now access real-time data for dose optimization and lifestyle adjustments, enhancing personalized care. Interoperability between monitoring devices and insulin delivery systems is improving usability, particularly for pediatric and elderly populations.

Healthcare systems are gradually adopting value-based care models, which emphasize outcome-driven interventions. This shift is encouraging use of therapies and devices that offer long-term benefits such as reduced hospitalization, improved quality of life, and prevention of complications. Growth in telemedicine and home health services is further supporting decentralization of diabetes care. Insurance reimbursement for advanced therapies and inclusion in national diabetes programs are helping accelerate adoption, especially in developed markets.

What Factors Are Driving Growth in the Next Generation Diabetes Therapy and Drug Delivery Market?

Growth in the next generation diabetes therapy and drug delivery market is driven by several factors. Rising global prevalence of diabetes is creating sustained need for innovative and efficient treatment models. Introduction of novel drug classes with extended half-lives and cardiometabolic benefits is reshaping pharmacological strategies. Advancements in smart delivery systems, including closed-loop pumps and wearable injectors, are improving control and patient autonomy. Digital integration and remote care enablement are enhancing treatment personalization and clinical oversight. Expansion of reimbursement coverage and regulatory support for integrated solutions are facilitating faster market entry and broader access. These trends are collectively redefining diabetes management, driving demand for advanced therapies and next-generation delivery technologies.

SCOPE OF STUDY:

The report analyzes the Next Generation Diabetes Therapy and Drug Delivery market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, Artificial Pancreas); Indication (Type 1 Diabetes, Type 2 Diabetes); End-Use (Diagnostics / Clinics End-Use, Intensive Care Units End-Use, Home Healthcare End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 43 Featured) -

  • Abbott Laboratories
  • Beta Bionics, Inc.
  • Camurus AB
  • Dexcom, Inc.
  • Eli Lilly and Company
  • Enteris BioPharma
  • GlySens Incorporated
  • Johnson & Johnson
  • MannKind Corporation
  • Medtech S.A.
  • Medtronic plc
  • Nemaura Medical Inc.
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Relmada Therapeutics
  • Roche Holding AG
  • Sanofi S.A.
  • Senseonics Holding, Inc.
  • Tandem Diabetes Care, Inc.
  • Ypsomed AG
  • Zosano Pharma Corp.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Next Generation Diabetes Therapy and Drug Delivery - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Diabetes Prevalence Drives Demand for Innovative Therapy and Delivery Solutions
    • Shift Toward Patient-Centric Care Models Propels Adoption of Personalized Diabetes Treatments
    • Advancements in Continuous Glucose Monitoring (CGM) Systems Enhance Insulin Delivery Accuracy
    • Integration of AI and Data Analytics into Drug Delivery Devices Strengthens Disease Management
    • Growing Use of Smart Insulin Pens and Connected Devices Supports Real-Time Dose Optimization
    • Development of Non-Invasive Insulin Delivery Systems Expands Market Accessibility
    • Emergence of Dual and Triple Agonists for Type 2 Diabetes Therapy Accelerates Pipeline Innovation
    • Increasing Preference for Oral GLP-1 Receptor Agonists Enhances Patient Compliance
    • Focus on Minimally Invasive Technologies Spurs Growth in Microneedle Patch Development
    • Expansion of Closed-Loop Insulin Delivery Systems Throws the Spotlight on Automated Diabetes Care
    • Patient Demand for Discreet, Portable Delivery Systems Drives Design Evolution in Wearable Injectors
    • Investment in Regenerative Therapies Including Stem Cell-Based Interventions Fuels Long-Term Research
    • Rising Burden of Diabetes in Low and Middle-Income Countries Expands Scope for Cost-Effective Delivery Options
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Next Generation Diabetes Therapy and Drug Delivery Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Inhalable Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Inhalable Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Oral Insulin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Oral Insulin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Insulin Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Insulin Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for CGM Systems by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for CGM Systems by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Artificial Pancreas by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Artificial Pancreas by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Home Healthcare End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Home Healthcare End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostics / Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Diagnostics / Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Intensive Care Units End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Intensive Care Units End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Type 1 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Type 1 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Type 2 Diabetes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Type 2 Diabetes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • JAPAN
    • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • CHINA
    • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • EUROPE
    • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • FRANCE
    • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • GERMANY
    • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • UNITED KINGDOM
    • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Next Generation Diabetes Therapy and Drug Delivery Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Product Type - Percentage Breakdown of Value Sales for Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems and Artificial Pancreas for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by End-Use - Percentage Breakdown of Value Sales for Home Healthcare End-Use, Diagnostics / Clinics End-Use and Intensive Care Units End-Use for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Next Generation Diabetes Therapy and Drug Delivery by Indication - Type 1 Diabetes and Type 2 Diabetes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Next Generation Diabetes Therapy and Drug Delivery by Indication - Percentage Breakdown of Value Sales for Type 1 Diabetes and Type 2 Diabetes for the Years 2025 & 2030

IV. COMPETITION